Jade Biosciences, Inc. (JBIO) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Jade Biosciences, Inc. (JBIO) closed at USD 13.44 on 2026-10-14, a change of +37.3 % over the past year, with a market capitalization of USD 875.1M.

Jade Biosciences, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Jade Biosciences, Inc. key figures

Previous close

USD 13.44 (2026-10-14)

1-year change

+37.3 %

Market cap

USD 875.1M

Enterprise value

USD 415.29M

P/E ratio (trailing)

-6.99

P/E ratio (forward)

-5.17

EPS (trailing)

-1.97

EPS (forward)

-2.66

PEG ratio

n/a

Price to book

1.99

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

12.01

Employees

55

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Jade Biosciences, Inc.

Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Jade Biosciences, Inc. and compare it with other stocks.